{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06119685",
            "orgStudyIdInfo": {
                "id": "Indapta-Trial-1"
            },
            "organization": {
                "fullName": "Indapta Therapeutics, INC.",
                "class": "INDUSTRY"
            },
            "briefTitle": "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers",
            "officialTitle": "Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "idp-as-a-single-agent-and-in-combination-with-antibody-therapies-in-patients-with-advanced-hematologic-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-22",
            "studyFirstSubmitQcDate": "2023-10-31",
            "studyFirstPostDateStruct": {
                "date": "2023-11-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Indapta Therapeutics, INC.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.",
            "detailedDescription": "IDP-023 is an off-the-shelf, allogeneic cell product made of \"natural killer\" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells.\n\nThis is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab to evaluate the safety, tolerability, and preliminary antitumor activity in patients with relapsed and/or refractory advanced multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL), respectively.\n\nThe study is divided into a phase 1 dose escalation phase and a phase 2 expansion phase.\n\nPhase 1 (Escalation Phase): The primary objectives of Phase 1 are to define the safety of different IDP-023 containing regimens and to define the recommended regimen and Phase 2 doses (RP2D) of IDP-023.\n\nPhase 2 (Expansion Phase): The objective of the Phase 2 expansion cohort is to evaluate the safety and efficacy of IDP-023 in advanced MM in combination with daratumumab and advanced NHL in combination with rituximab."
        },
        "conditionsModule": {
            "conditions": [
                "NHL",
                "Multiple Myeloma",
                "Blood Cancer",
                "Refractory Non-Hodgkin Lymphoma",
                "Relapsed Non-Hodgkin Lymphoma",
                "Refractory Multiple Myeloma",
                "Relapsed Multiple Myeloma"
            ],
            "keywords": [
                "Advanced Hematologic Cancers"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 128,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1: Single Agent IDP-023 - Single Dose",
                    "type": "EXPERIMENTAL",
                    "description": "NHL or MM patient treated with a single dose of IDP-023 monotherapy",
                    "interventionNames": [
                        "Drug: IDP-023",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna"
                    ]
                },
                {
                    "label": "Phase 1: Single Agent IDP-023 - Multiple Doses",
                    "type": "EXPERIMENTAL",
                    "description": "NHL and MM patients treated with multiple doses of IDP-023 monotherapy",
                    "interventionNames": [
                        "Drug: IDP-023",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna"
                    ]
                },
                {
                    "label": "Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",
                    "type": "EXPERIMENTAL",
                    "description": "NHL and MM patients treated with multiple doses of IDP-023 monotherapy",
                    "interventionNames": [
                        "Drug: IDP-023",
                        "Drug: Interleukin-2",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna"
                    ]
                },
                {
                    "label": "Phase 2: Combination IDP-023 plus rituximab",
                    "type": "EXPERIMENTAL",
                    "description": "NHL patients treated with multiple doses of IDP-023 in combination with rituximab",
                    "interventionNames": [
                        "Drug: IDP-023",
                        "Drug: Rituximab",
                        "Drug: Interleukin-2",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna"
                    ]
                },
                {
                    "label": "Phase 2: Combination IDP-023 plus daratumumab",
                    "type": "EXPERIMENTAL",
                    "description": "MM patients treated with multiple doses of IDP-023 in combination with daratumumab",
                    "interventionNames": [
                        "Drug: IDP-023",
                        "Drug: Daratumumab",
                        "Drug: Interleukin-2",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "IDP-023",
                    "description": "NK cell therapy",
                    "armGroupLabels": [
                        "Phase 1: Single Agent IDP-023 - Multiple Doses",
                        "Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",
                        "Phase 1: Single Agent IDP-023 - Single Dose",
                        "Phase 2: Combination IDP-023 plus daratumumab",
                        "Phase 2: Combination IDP-023 plus rituximab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "Anti-CD20 antibody therapy",
                    "armGroupLabels": [
                        "Phase 2: Combination IDP-023 plus rituximab"
                    ],
                    "otherNames": [
                        "Rituxan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Daratumumab",
                    "description": "Anti-CD38 antibody therapy",
                    "armGroupLabels": [
                        "Phase 2: Combination IDP-023 plus daratumumab"
                    ],
                    "otherNames": [
                        "Darzalex"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Interleukin-2",
                    "description": "Immune cytokine",
                    "armGroupLabels": [
                        "Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",
                        "Phase 2: Combination IDP-023 plus daratumumab",
                        "Phase 2: Combination IDP-023 plus rituximab"
                    ],
                    "otherNames": [
                        "Proleukin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lymphodepleting chemotherapy",
                    "armGroupLabels": [
                        "Phase 1: Single Agent IDP-023 - Multiple Doses",
                        "Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",
                        "Phase 1: Single Agent IDP-023 - Single Dose",
                        "Phase 2: Combination IDP-023 plus daratumumab",
                        "Phase 2: Combination IDP-023 plus rituximab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lymphodepleting chemotherapy",
                    "armGroupLabels": [
                        "Phase 1: Single Agent IDP-023 - Multiple Doses",
                        "Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",
                        "Phase 1: Single Agent IDP-023 - Single Dose",
                        "Phase 2: Combination IDP-023 plus daratumumab",
                        "Phase 2: Combination IDP-023 plus rituximab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Mesna",
                    "description": "Chemoprotectant",
                    "armGroupLabels": [
                        "Phase 1: Single Agent IDP-023 - Multiple Doses",
                        "Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2",
                        "Phase 1: Single Agent IDP-023 - Single Dose",
                        "Phase 2: Combination IDP-023 plus daratumumab",
                        "Phase 2: Combination IDP-023 plus rituximab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Incidence of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "up to 21 days"
                },
                {
                    "measure": "Nature of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "up to 21 days"
                },
                {
                    "measure": "Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with Daratumumab or Rituximab - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "up to 35 days"
                },
                {
                    "measure": "Nature of dose-limiting toxicities (DLTs) of IDP-023 in combination with Daratumumab or Rituximab - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "up to 35 days"
                },
                {
                    "measure": "Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 2)",
                    "description": "Expansion period",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 2)",
                    "description": "Expansion period",
                    "timeFrame": "2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK (Cmax) of IDP-023 - (Phase 1/2)",
                    "description": "Escalation and expansion periods",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "PK (AUC) of IDP-023 - (Phase 1/2)",
                    "description": "Escalation and expansion periods",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 1)",
                    "description": "Escalation period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 1)",
                    "description": "Escalation period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 2)",
                    "description": "Expansion period",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after \u2265 3 prior lines of therapy.\n* For NHL patients: R/R disease and failed \u2265 2 lines of systemic chemotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of greater than 12 weeks per the Investigator.\n\nKey Exclusion Criteria:\n\n* Impaired cardiac function or history of clinical significant cardiac disease.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Indapta Therapeutics, Inc.",
                    "role": "CONTACT",
                    "email": "TRIALS@INDAPTA.COM"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Indapta Therapeutics, Inc.",
                    "affiliation": "Indapta Therapeutics, INC.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                },
                {
                    "facility": "Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lacey Gebben",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "407-804-6133",
                            "phoneExt": "26446",
                            "email": "lacey.gebben@flcancer.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "Emory University Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kayla Wagenmann, MN, RN, PHN",
                            "role": "CONTACT",
                            "phone": "612-624-2342",
                            "email": "wage0074@umn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "NYP/Weill Cornell Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anita Margarette Bayya Ventura",
                            "role": "CONTACT",
                            "phone": "646-962-9336",
                            "email": "abv4001@med.cornell.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Atrium Health Wake Forest Baptist",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27157",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                },
                {
                    "facility": "University Hospitals Cleveland",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Providence Cancer Institute Franz Clinic",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katrina Herz",
                            "role": "CONTACT",
                            "phone": "503-215-2617",
                            "email": "Katrina.Herz@providence.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Rhode Island Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02903",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephen Donnelly",
                            "role": "CONTACT",
                            "phone": "401-444-4822",
                            "email": "SDonnelly1@Lifespan.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christy Allen",
                            "role": "CONTACT",
                            "phone": "281-455-0250",
                            "email": "callen6@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Blake Patterson",
                            "role": "CONTACT",
                            "phone": "703-783-4505",
                            "email": "bpatterson@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "D000007376",
                    "term": "Interleukin-2"
                },
                {
                    "id": "C000556306",
                    "term": "Daratumumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M272211",
                    "name": "Daratumumab",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10411",
                    "name": "Interleukin-2",
                    "asFound": "Reconstruction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M225496",
                    "name": "Aldesleukin",
                    "relevance": "LOW"
                },
                {
                    "id": "M17811",
                    "name": "Mesna",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}